Subscribe: Gist E-Paper
The first volunteer has received a dose in a first-in-human trial of Oxford’s Lassa vaccine, marking a major milestone in the fight against the deadly virus.
This was disclosed on Thursday by the Coalition for Epidemic Preparedness Innovations on its website.
CEPI is an innovative partnership between public, private, philanthropic, and civil organisations. Its mission is to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats so they can be accessible to all people in need.
The trial, conducted by the Oxford Vaccine Group and funded by CEPI, will assess the safety and immune response of the ChAdOx1 Lassa vaccine.
